Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 10, 2026
MP Materials (MP) vs United States Antimony (UAMY): Weighing Two Critical Minerals Stocks

MP Materials (MP) vs United States Antimony (UAMY): Weighing Two Critical Minerals Stocks

Key Takeaways

  • MP is a leading U.S. rare earth producer with integrated mining and magnet manufacturing, benefiting from government price support and defense initiatives.
  • UAMY focuses on antimony and related critical minerals, recently securing a major $245 million U.S. Defense Logistics Agency contract that has driven sharp revenue growth.
  • In recent market activity, MP has shown steady performance with Q2 results beating expectations amid broader critical minerals demand, while UAMY has exhibited higher volatility and stronger year-to-date returns.
  • Both companies operate in the industrial metals and mining sector with exposure to defense, electric vehicles, and renewable energy supply chains, though MP emphasizes rare earth elements like NdPr and UAMY centers on antimony processing.
  • Risk factors include commodity price fluctuations and geopolitical tensions for both, with MP offering greater scale and UAMY demonstrating rapid contract-driven momentum.
  • Market sentiment remains positive for critical minerals stocks overall, supported by U.S. efforts to reduce reliance on foreign supply chains.

Why These Two Matter in the Current Environment

This comparison examines MP and UAMY, two companies in the critical minerals space that support U.S. strategic priorities in defense, clean energy, and advanced manufacturing. Traders and investors focused on sector rotation, supply chain resilience, or small- to mid-cap materials plays may find the analysis relevant for assessing relative positioning, recent momentum, and operational contrasts in the current environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

MP Materials: Established Scale in Rare Earths

MP Materials Corp. operates the Mountain Pass rare earth mine and processing facility in California, producing materials such as neodymium-praseodymium (NdPr) used in permanent magnets for electric vehicles, wind turbines, and defense applications. In recent weeks, the stock has reflected broader sector interest following second-quarter results that showed revenue growth, increased NdPr production, and benefits from U.S. government price support agreements. Performance has been influenced by sustained demand for domestic rare earth supply chains and analyst attention on vertical integration progress, though the shares have traded within a wider 52-week range amid commodity price variability.

United States Antimony: Contract Momentum and Volatility

United States Antimony Corp. engages in the extraction, processing, and sale of antimony, zeolite, and precious metals, with operations supporting industrial and defense uses. Recent market activity has highlighted a significant contract win with the U.S. Defense Logistics Agency, alongside reported year-over-year revenue expansion in the latest quarter. The stock has displayed notable price swings, consistent with its smaller scale and sensitivity to contract announcements and critical minerals sentiment, while maintaining elevated trading volumes in the period. From what I see, this contract news has been a key driver worth monitoring closely.

Head-to-Head Comparison

MP operates at greater scale with a fully integrated rare earth supply chain, providing stability through established production volumes and government-backed initiatives, whereas UAMY offers higher growth potential tied to antimony demand and recent contract catalysts but with greater earnings volatility. Growth drivers differ: MP benefits from magnet manufacturing expansion and NdPr output increases, while UAMY leverages antimony’s role in flame retardants, batteries, and defense. Recent momentum favors UAMY on a relative return basis amid contract news, though MP has shown more consistent earnings beats. Risk factors for both include input cost pressures and global trade dynamics, with MP carrying exposure to rare earth pricing and UAMY to smaller-cap liquidity considerations. Sector exposure overlaps in critical minerals, yet MP aligns more closely with magnet and EV themes while UAMY emphasizes antimony-specific applications. Overall market sentiment supports both amid U.S. reshoring efforts, creating trade-offs between established infrastructure and contract-driven upside.

AI Verdict on Relative Positioning

Based on observable factors such as recent contract momentum, revenue trajectory, and relative positioning within critical minerals, Tickeron’s AI models would currently assign a higher probabilistic favor to UAMY over MP, though outcomes remain subject to ongoing volatility and sector-wide variables. MP demonstrates stronger trend consistency through production scaling and support mechanisms, providing a more stable profile for longer-horizon considerations. One thing that stands out is how these models highlight the balance between stability and upside potential.

Tools I Use for Deeper Analysis

In my own work on stocks like these, Tickeron’s AI Trading Bots have proven helpful for testing strategies across different market conditions. The platform provides performance metrics on hundreds of bots, allowing me to explore win rates, profit factors, and drawdowns tailored to volatile sectors without real capital at risk. It adds a practical layer to evaluating relative opportunities in critical minerals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UAMY, MP

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


UAMY in upward trend: price rose above 50-day moving average on August 07, 2026

UAMY moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend. In of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UAMY's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on UAMY as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for UAMY just turned positive on July 31, 2026. Looking at past instances where UAMY's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where UAMY advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 50-day moving average for UAMY moved below the 200-day moving average on July 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UAMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

UAMY broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for UAMY entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UAMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UAMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.698) is normal, around the industry mean (11.557). P/E Ratio (0.000) is within average values for comparable stocks, (130.643). UAMY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.295). UAMY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (22.936) is also within normal values, averaging (294.079).

Notable companies

The most notable companies in this group are BHP Group Limited (NYSE:BHP), Vale SA (NYSE:VALE).

Industry description

The category includes companies that explore for, mine and extract metals, such as copper, diamonds, nickel, cobalt ore, lead, zinc and uranium. BHP, Rio Tinto and Southern Copper Corporation are major players in this space.

Market Cap

The average market capitalization across the Other Metals/Minerals Industry is 9.45B. The market cap for tickers in the group ranges from 230 to 225B. BHP holds the highest valuation in this group at 225B. The lowest valued company is BAJFF at 230.

High and low price notable news

The average weekly price growth across all stocks in the Other Metals/Minerals Industry was 19%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -14%. WWR experienced the highest price growth at 86%, while EMAT experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Other Metals/Minerals Industry was 176%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 92
Profit Risk Rating: 87
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
UAMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer of antimony products

Industry OtherMetalsMinerals

Profile
Details
Industry
Metal Fabrication
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.